199 related articles for article (PubMed ID: 11508158)
1. [Tumor-induced hypercalcemia. Review of bisphosphonate treatment].
Lortholary A
Rev Med Interne; 2001 Jul; 22(7):648-52. PubMed ID: 11508158
[TBL] [Abstract][Full Text] [Related]
2. Hypercalcemia of malignancy.
Body JJ
Semin Nephrol; 2004 Jan; 24(1):48-54. PubMed ID: 14730509
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hypercalcemia of malignancy with bisphosphonates.
Berenson JR
Semin Oncol; 2002 Dec; 29(6 Suppl 21):12-8. PubMed ID: 12584690
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid: a new parenteral bisphosphonate.
Li EC; Davis LE
Clin Ther; 2003 Nov; 25(11):2669-708. PubMed ID: 14693298
[TBL] [Abstract][Full Text] [Related]
5. Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia.
Body JJ; Louviaux I; Dumon JC
Support Care Cancer; 2000 Sep; 8(5):398-404. PubMed ID: 10975689
[TBL] [Abstract][Full Text] [Related]
6. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
Major P
Oncologist; 2002; 7(6):481-91. PubMed ID: 12490736
[TBL] [Abstract][Full Text] [Related]
7. Metastatic bone disease and tumour-induced hypercalcaemia: the role of bisphosphonates.
Heatley S
Int J Palliat Nurs; 2001 Jun; 7(6):301-2, 304-7. PubMed ID: 12066026
[TBL] [Abstract][Full Text] [Related]
8. Current and future directions in medical therapy: hypercalcemia.
Body JJ
Cancer; 2000 Jun; 88(12 Suppl):3054-8. PubMed ID: 10898351
[TBL] [Abstract][Full Text] [Related]
9. Modern management of malignant hypercalcemia.
Legrand SB
Am J Hosp Palliat Care; 2011 Nov; 28(7):515-7. PubMed ID: 21724679
[TBL] [Abstract][Full Text] [Related]
10. Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome.
Wenzel C; Bartsch R; Hussian D; Pluschnig U; Locker GJ; Sevelda U; Zielinski CC; Steger GG
Support Care Cancer; 2004 Sep; 12(9):678-81. PubMed ID: 15160319
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy.
Coleman RE
Oncology (Williston Park); 1991 Aug; 5(8):55-60; discussion 60-2, 65. PubMed ID: 1834153
[TBL] [Abstract][Full Text] [Related]
12. Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride.
Harinck HI; Bijvoet OL; Plantingh AS; Body JJ; Elte JW; Sleeboom HP; Wildiers J; Neijt JP
Am J Med; 1987 Jun; 82(6):1133-42. PubMed ID: 3300303
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
14. [How to treat tumor-induced hypercalcemia].
Body JJ
Rev Prat; 2003 Dec; 53(19):2128-35. PubMed ID: 15008469
[TBL] [Abstract][Full Text] [Related]
15. Hypercalcemia of malignancy remains a clinically relevant problem.
Van Poznak C
Cancer J; 2006; 12(1):21-3. PubMed ID: 16613658
[No Abstract] [Full Text] [Related]
16. Update on the medical treatment of hypercalcemia of malignancy.
Hall TG; Schaiff RA
Clin Pharm; 1993 Feb; 12(2):117-25. PubMed ID: 8453860
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Hypercalcemia of Malignancy.
Chakhtoura M; El-Hajj Fuleihan G
Endocrinol Metab Clin North Am; 2021 Dec; 50(4):781-792. PubMed ID: 34774248
[TBL] [Abstract][Full Text] [Related]
18. Newer agents for the treatment of malignant hypercalcemia.
Kinirons MT
Am J Med Sci; 1993 Jun; 305(6):403-6. PubMed ID: 8506902
[TBL] [Abstract][Full Text] [Related]
19. Advances in the biology and treatment of myeloma bone disease.
Berenson JR
Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S16-20. PubMed ID: 11757204
[TBL] [Abstract][Full Text] [Related]
20. Bone metastases and tumor-induced hypercalcemia.
Body JJ
Curr Opin Oncol; 1992 Aug; 4(4):624-31. PubMed ID: 1511019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
